Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T-cells (ACTolog; IMA101) in Patients With Relapsed and/or Refractory Solid Cancers

Trial Profile

Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T-cells (ACTolog; IMA101) in Patients With Relapsed and/or Refractory Solid Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; IMA 101 (Primary) ; Interleukin-2 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms ACTolog
  • Sponsors Immatics US
  • Most Recent Events

    • 05 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 16 May 2017 Planned initiation date changed from 31 Oct 2017 to 1 Jul 2017.
    • 09 May 2017 Planned End Date changed from 1 Sep 2018 to 31 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top